

11/10/03

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	Not yet known 10/705,183
				Filing Date	Herewith
				First Named Inventor	Stephen D. HURST
				Art Unit	Not yet known 1646
				Examiner Name	Not yet known
Sheet	1	of	3	Attorney Docket Number	DX01088KB D. Jiang

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
DJ	AA	U.S. 6,562,578	05-13-2003	GORMAN, et al.	Columns 1-2, 4, 6-7, 42-43.
DJ	AB	U.S. 2003/0008815	01-09-2003	CHEN, et al.	Columns 14, 22, 23.

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
DJ	AC	WO 00/42188	07-20-2000	GORMAN, et al.	T <sup>6</sup>

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
DJ	AD	ASHOK R. AMIN and STEVEN B. ABRAMSON, <i>Curr. Op. Rheumatol.</i> , 10:263-268, 1998. "The role of nitric oxide in articular cartilage breakdown in osteoarthritis"			
DJ	AE	MARTINE CHABAUD, et al. <i>J. Immunol.</i> , 161: 409-414, 1998. "Enhancing effect of IL-17 on IL-1 Induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulations by Th2 Cytokines"			
DJ	AF	FRANCOIS FOSSIEZ, et al., <i>Int. Rev. Immunol.</i> , 16(5-6):541-551, 1998. "Interleukin-17"			
DJ	AG	MARY HITT, et al., <i>Advances in Pharmacology</i> , 40:137-206, 1997. "Human adenovirus vectors for gene transfer into mammalian cells"			

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				<b>C mplete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	Not yet known
(Use as many sheets as necessary)				Filing Date	Herewith
Sheet	2	of	3	First Named Inventor	Stephen D. HURST
				Art Unit	Not yet known
				Examiner Name	Not yet known
				Attorney Docket Number	DX01088KB

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
DJ	AH	NEIL W. ISAACS, <u>Curr. Op. Struct. Biol.</u> , 5:391-395, 1995. "Cystine knots"				
	AI	JACQUELINE KENNEDY, et al., <u>J. Interferon and Cytokine Research</u> , 16:611-617, 1996. "Mouse IL-17:a cytokine preferentially expressed by $\alpha\beta$ TCR $^*$ CD4 $^*$ CD8 $^*$ T Cells"				
	AJ	MEE RHAN KIM, et al., <u>Blood</u> , 100(7):2330-2340, Sept. 2002. "Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production"				
	AK	ANDREA KNAPPE, et al., <u>J. Virology</u> , 72(7):5797-5801, July 1998. "The Interleukin-17 gene of herpesvirus Saimiri"				
	AL	NEIL Q. MCDONALD and WAYNE A. HENDRICKSON, <u>Cell</u> , 73:421-424, May 7, 1993. "A structural superfamily of growth factors containing a cystine knot motif"				
	AM	G. PAN, et al., <u>J. Immunol.</u> , 167(11):6559-6567, 2001. "Forced expression of murine IL-17E induces growth, retardation, jaundice, a TH2-biased response, and multiorgan inflammation in mice"				
	AN	ERIC ROUVIER, et al., <u>J. Immunol.</u> , 150(12):5445-5456, June 15, 1993. "CTLA-8, cloned from an activated T cell, bearing AU-Rich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene"				
	AO	HENG-FONG SEOW, <u>Vet. Immunol. Immunopath.</u> , 63:139-148, 1998. "Pathogen interactions with cytokines and host defence: an overview"				
	AP	TALI SHALOM-BARAK, et al., <u>J. Biol. Chem.</u> , 273 (42): 27467-27473, October 16, 1998. "Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF- $\kappa$ B"				
	AQ	PETER D. SUN and DAVID R. DAVIES, <u>Annu. Rev. Biophys. Biomol. Struct.</u> , 24:269-291, 1995. "The cystine-knot growth-Factor superfamily"				
↓	AR	MARCEL TEUNNISON, et. al., <u>J. Invest. Dermatol.</u> , 111:645-649, 1998. "Interleukin-17 and Interferon- $\gamma$ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes"				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**

<p>Substitute for form 1449/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	Not yet known 10/705,183
				Filing Date	Herewith
				First Named Inventor	Stephen D. HURST
				Art Unit	Not yet known 1646
				Examiner Name	Not yet known D. Jiang
Sheet	3	of	3	Attorney Docket Number	DX01088KB

Examiner Signature	/Dong Jiang/	Date Considered	11/21/2006
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.